Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

07 oct. 2014 08h00 HE | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Clinical Data Presentations at the 2014 American Academy of Ophthalmology Scientific Meeting

NEW YORK, Oct. 7, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that additional positive anatomic and visual...
09 sept. 2014 09h00 HE | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Clinical Data Presentations at the Retina Society 47th Annual Scientific Meeting

NEW YORK, Sept. 9, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that data from the IMPACT study, a phase II...
13 août 2014 08h30 HE | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces Additional Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Wet-AMD; The IMPACT Study

NEW YORK, Aug. 13, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced additional interim data from the Phase II study...
11 août 2014 09h00 HE | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Retinal Vein Occlusion

NEW YORK, Aug. 11, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced data supporting the use of Squalamine Eye Drops...
08 août 2014 08h00 HE | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical to Present at the 2014 Wedbush Life Sciences Management Access Conference

NEW YORK, Aug. 8, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Sam Backenroth, Chief Financial Officer, will...
07 août 2014 09h00 HE | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces Upcoming Squalamine Eye Drop Clinical Data Presentations at the 2014 Annual Meeting of the American Society of Retina Specialists

NEW YORK, Aug. 7, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that data from clinical studies evaluating...
26 juin 2014 09h00 HE | Source: Vista Partners LLC

Vista Partners Updates Coverage on Ohr Pharmaceutical, Inc. (NASDAQ: OHRP); Raises Price Target to $31

SAN FRANCISCO, CA--(Marketwired - Jun 26, 2014) - Vista Partners announced today that it has updated coverage on Ohr Pharmaceutical, Inc. (NASDAQ: OHRP) ("The Company" or "OHR") and raised its...
24 juin 2014 07h00 HE | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces Positive Interim Top-Line Clinical Results From Phase II Study of Squalamine Eye Drops in Patients With Wet AMD

Patients treated with Squalamine eye drops plus Lucentis® PRN demonstrated a 65 percent additional relative benefit in visual acuity versus placebo eye drops plus Lucentis PRN Percentage...
23 juin 2014 16h30 HE | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical to Host Conference Call and Webcast to Discuss Squalamine Interim Phase II Data in Wet-AMD

Webcast to be Held on Tuesday, June 24 at 8:30am Eastern Webcast & Slides Available at www.OhrPharmaceutical.com NEW YORK, June 23, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc....
03 juin 2014 09h00 HE | Source: Vista Partners LLC

Vista Partners Publishes June 2014 Macroeconomic & Investment Newsletter

SAN FRANCISCO, CA--(Marketwired - Jun 3, 2014) - Vista Partners ("Vista") published its FREE Macroeconomic & Investment Monthly Newsletter for the month of June. Each monthly newsletter from...

Page précédente

Page suivante